These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24602469)

  • 1. Optimizing blood pressure control in patients with nondiabetic glomerular disease.
    Umanath K; Lewis JB; Dwyer JP
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):200-4. PubMed ID: 24602469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High level of proteinuria during treatment with renin-angiotensin inhibitors is a strong predictor of renal outcome in nondiabetic kidney disease.
    Xie D; Hou FF; Fu BL; Zhang X; Liang M
    J Clin Pharmacol; 2011 Jul; 51(7):1025-34. PubMed ID: 20978279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there added value to adding ARB to ACE inhibitors in the management of CKD?
    Cohen DL; Townsend RR
    J Am Soc Nephrol; 2009 Aug; 20(8):1666-8. PubMed ID: 18776118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stage IV chronic kidney disease.
    Hirsch S
    N Engl J Med; 2010 May; 362(20):1942-3; author reply 1943. PubMed ID: 20496469
    [No Abstract]   [Full Text] [Related]  

  • 7. [Chronic kidney disease: therapy and care].
    Noel N; Gaha K; Rieu P
    Rev Prat; 2012 Jan; 62(1):43-51. PubMed ID: 22335066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
    Kincaid-Smith P; Fairley KF; Packham D
    Nephrol Dial Transplant; 2004 Sep; 19(9):2272-4. PubMed ID: 15252156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of dietary sodium restriction in the management of chronic kidney disease.
    Krikken JA; Laverman GD; Navis G
    Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):531-8. PubMed ID: 19713840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Remission Clinic approach to halt the progression of kidney disease.
    ;
    J Nephrol; 2011; 24(3):274-81. PubMed ID: 21534237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease.
    Linas SL
    Clin J Am Soc Nephrol; 2008 Jan; 3 Suppl 1(Suppl 1):S17-23. PubMed ID: 18178792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent update in the management of hypertension.
    Lim S
    Acta Med Indones; 2007; 39(4):186-91. PubMed ID: 18380058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers after renal transplantation.
    Morath C; Schmied B; Mehrabi A; Weitz J; Schmidt J; Werner J; Buchler MW; Morcos M; Nawroth PP; Schwenger V; Doehler B; Opelz G; Zeier M
    Clin Transplant; 2009 Dec; 23 Suppl 21():33-6. PubMed ID: 19930314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood pressure control in patients with chronic renal insufficiency in Spain: a cross-sectional study.
    Marín R; Fernández-Vega F; Gorostidi M; Ruilope LM; Díez J; Praga M; Herrero P; Alcázar JM; Laviades C; Aranda P;
    J Hypertens; 2006 Feb; 24(2):395-402. PubMed ID: 16508589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success.
    Hirsch S; Hirsch J; Bhatt U; Rovin BH
    Am J Nephrol; 2012; 36(5):430-7. PubMed ID: 23128144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of baroreflex activation therapy on renal function--a pilot study.
    Wallbach M; Lehnig LY; Schroer C; Hasenfuss G; Müller GA; Wachter R; Koziolek MJ
    Am J Nephrol; 2014; 40(4):371-80. PubMed ID: 25358549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R; Palmer BF
    Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strict blood-pressure control and progression of renal failure in children.
    ; Wühl E; Trivelli A; Picca S; Litwin M; Peco-Antic A; Zurowska A; Testa S; Jankauskiene A; Emre S; Caldas-Afonso A; Anarat A; Niaudet P; Mir S; Bakkaloglu A; Enke B; Montini G; Wingen AM; Sallay P; Jeck N; Berg U; Caliskan S; Wygoda S; Hohbach-Hohenfellner K; Dusek J; Urasinski T; Arbeiter K; Neuhaus T; Gellermann J; Drozdz D; Fischbach M; Möller K; Wigger M; Peruzzi L; Mehls O; Schaefer F
    N Engl J Med; 2009 Oct; 361(17):1639-50. PubMed ID: 19846849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.